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Abstract
Background: The fibroblast growth factors (FGFs) are key regulators of embryonic development, tissue homeostasis and
tumour angiogenesis. Binding of FGFs to their receptor(s) results in activation of several intracellular signalling cascades
including phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC)c1. Here we investigated the basic FGF (FGF-2)-
mediated activation of these enzymes in human umbilical vein endothelial cells (HUVECs) and defined their role in FGF-2-
dependent cellular functions.
Methodology/Principal Findings: We show that FGF-2 activates PLCc1 in HUVECs measured by analysis of total inositol
phosphates production upon metabolic labelling of cells and intracellular calcium increase. We further demonstrate that
FGF-2 activates PI3K, assessed by analysing accumulation of its lipid product phosphatidylinositol-3,4,5-P3 using TLC and
confocal microscopy analysis. PI3K activity is required for FGF-2-induced PLCc1 activation and the PI3K/PLCc1 pathway is
involved in FGF-2-dependent cell migration, determined using Transwell assay, and in FGF-2-induced capillary tube
formation (tubulogenesis assays in vitro). Finally we show that PI3K-dependent PLCc1 activation regulates FGF-2-mediated
phosphorylation of Akt at its residue Ser473, determined by Western blotting analysis. This occurs through protein kinase C
(PKC)a activation since dowregulation of PKCa expression using specific siRNA or blockade of its activity using chemical
inhibition affects the FGF-2-dependent Ser473 Akt phosphorylation. Furthermore inhibition of PKCa blocks FGF-2-
dependent cell migration.
Conclusion/Significance: These data elucidate the role of PLCc1 in FGF-2 signalling in HUVECs demonstrating its key role in
FGF-2-dependent tubulogenesis. Furthermore these data unveil a novel role for PLCc1 as a mediator of PI3K-dependent Akt
activation and as a novel key regulator of different Akt-dependent processes.
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Introduction
Angiogenesis, the formation of new vessels from existing
vasculature, is required for different physiological processes such
as development, reproduction, wound healing, and tissue regen-
eration [1]. On the other hand angiogenesis is involved in
pathologies such as arteriosclerosis, diabetic retinopathy, rheuma-
toid arthritis and tumour growth [2,3]. Angiogenesis consists of a
multistep process involving capillary endothelial cell (EC)
migration and proliferation and the formation of three-dimen-
sional structures capable of carrying blood [1]. A complex network
of growth factors and cytokines regulates angiogenesis including
the family of vascular endothelial growth factor (VEGFs) and
fibroblast growth factor (FGFs) [4]. The signalling pathways
activated by VEGFs have been extensively investigated in
physiological and pathological angiogenesis. For instance the key
role of VEGFs in tumour angiogenesis is well recognised [5,6] and
several anti-angiogenic agents targeting VEGFs signalling are now
available for anti-cancer strategy. The FGFs family consists of at
least 22 factors that play a crucial role in morphogenesis during
embryo development and in control of the nervous system, tissue
repair and wound healing in the adult organism [7]. On the other
hand, several lines of evidence indicate that FGFs, in particular
FGF-2, play a key role in tumour angiogenesis [8]. For instance
FGF-2 is frequently highly expressed in highly vascularized and
advanced cancers [9–11] and it has been reported that a
synergistic action of FGF-2 and platelet derived growth factor-
BB promotes tumour angiogenesis and pulmonary metastasis in
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with resistance to anti-VEGF agents [13]. Germline mutations in
FGF receptors have been detected in different cancer types [14]
and data suggest that inhibitions of these receptors through small
molecule inhibitors or antibodies may be of clinical value [14].
Binding of VEGFs and FGFs to their respective receptors leads
to receptor phosphorylation and subsequent activation of
signalling proteins including the Ras pathway, the Src family
tyrosine kinases, phosphoinositide 3-kinase (PI3K) and phospho-
lipase C (PLC)c1.
PI3Ks are a conserved family of lipid kinases that catalyze the
phosphorylation of the D3 position of the inositol ring of
phosphoinositides at the plasma membrane or in specific cellular
membrane compartments. Interaction between the newly gener-
ated 3-phosphorylated phosphoinositides and distinct structural
motifs, such as pleckstrin homology (PH) domain, can regulate the
activity of different proteins through their membrane targeting or
direct modulation of their enzymatic activity [15]. Among such
proteins the serine/threonine kinase protein kinase B (PKB)/Akt,
an enzyme involved in diverse intracellular events including cell
proliferation, migration, survival and cell cycle progression, is
undoubtedly the most studied and best characterised. Several lines
of evidence indicate that PI3K plays an important role in VEGF
signalling, angiogenesis and regulation of VEGF expression [16].
While the VEGF-dependent activation of PI3K has been
extensively studied, the mechanism of FGF-mediated activation
of PI3K has been controversial until few years ago when it was
demonstrated that a growth factor-induced coordinated assembly
of a multi-docking protein complex is necessary for the FGF-2-
mediated activation of PI3K [17].
PLCc1 hydrolyzes phosphatidylinositol-4,5-bisphosphate to gen-
erate the second messengers inositol-1,4,5-trisphosphate and
diacylglycerol which in turn can activate several downstream
effectors including specific protein kinase C (PKC) isoforms leading
to many cellular responses [18]. Several lines of evidence indicate
that PLCc1 plays a critical role in angiogenesis, especially in VEGF
signalling with data suggesting a role for this enzyme in mediating
VEGF-induced cell proliferation and others revealing a role for
PLCc1 in stimulating VEGF-induced differentiation and tubulo-
genesis [19–21]. PLCc1 deletion results in reduced vasculogenesis
and erythropoiesis in mice [22] and in defects in artery formation in
transgenic zebrafish models [23]. The role of PLCc1 in FGF
signalling has been less investigated. Although the general
mechanism of PLCc1 activation involves its receptor-mediated
tyrosine phosphorylation, we demonstrated that PLCc1 can also be
activated downstream to PI3K in a mechanism involving the
interaction between its PH domain and the PI3K product
phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3) [24].
Here we show that FGF-2 activates PLCc1 in human umbilical
vein endothelial cells (HUVECs) and that this enzyme is critical for
the FGF-2-dependent cell migration and capillary tube formation
(angiogenesis in vitro). Moreover our data demonstrate that a PI3K-
dependent PLCc1 activation regulates FGF-2-mediated phos-
phorylation of Akt through PKCa activation, unveiling a novel
role for PLCc1 as a mediator of the PI3K-dependent Akt
activation and as a key regulator of different Akt-dependent
processes.
Materials and Methods
Materials
FGF-2 and VEGF were purchased from Peprotech, siGEN-
OME smartpool for PLCc1, PLCc2 and PKCa from Dharmacon;
scrambled siRNA from Ambion; U73122, U73343, LY294002,
Go ¨6976, PD98059 and U0126 from Calbiochem; SH5 from
Alexis Biochemicals; wortmannin from Sigma. Alternative siRNA
targeting PLCc2 was purchased from Qiagen. Anti PtdIns-3,4,5-
P3 was purchased from Echelon, anti PLCc1, anti Akt, anti actin,
anti PLCc2, anti ERK2, anti PKCa from Santa Cruz Biotech-
nology; anti pSer473 Akt from Cell Signaling Technology.
Cell lines and cultures
HUVEC were purchased from TCS CellWorks and grown in
EGM kit (EBM+singlequots, Lonza) supplemented with 10% FBS.
For expression of GFP-PH PLCc1, HUVEC were electroporated
as described [25]. Briefly, cells detached from a 10-cm cell culture
dish were resuspended in 400 ml of electroporation buffer (20 mM
Hepes pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4,
6 mM D-glucose) and incubated with 25 mg DNA in a cuvette for
10 min at room temperature. Cells were electroporated (960 mF,
200 V) by using a Bio-Rad Gene Pulser instrument (time constant
,26 sec) and then left in the cuvette for a further 10 min at room
temperature before plating.
For siRNA-based experiments, confluent HUVEC plated in 6
well plates were transfected by incubating in OPTIMEM
containing oligofectAMINE (Invitrogen) and 200 nM siRNA. After
24 h cells were serum starved overnight in M199+0.5% FBS before
being used for experiments. Alternatively, number of cells was
determined 24 h or 48 h after transfection by manual counting.
Inositol phosphates production
Cells were labelled with [
3H]myo inositol (PerkinElmer) in
inositol free medium M199 supplemented with 2% FBS. After
24 h, cells were incubated in M199 containing 10 mM Hepes and
20 mM LiCl for 15 min before stimulation, then lysed in 0.1 M
HCOOH. Total inositol phosphates were separated by anion
exchange chromatography by using AG 1-X8 resin (formate form,
200–400 mesh, BioRad) and the total amount assessed by liquid
radioactivity counting.
PI3K activation in vivo
PtdIns-3,4,5-P3 production was assessed by thin layer chroma-
tography (TLC) analysis as described [26]. Briefly, cells grown in a
6 well plate were incubated with 0.8 mCi/well [
32P]phosphoric
acid (PerkinElmer) in phosphate free medium M3786 (Sigma) for
3 h before stimulation as indicated. Phospholipids were extracted,
dried under nitrogen, resuspended in 100 ml chloroform:methanol
(3:2) and spotted onto silica plates pre-soaked in water:methanol
(3:2) containing 1.2% (w/v) oxalic acid and oven baked for 15 min
at 110uC. TLC plates were developed in chloroform: acetone:
methanol: acetic acid: water (90:36:30:27:18).
Migration and Tubulogenesis assay in vitro
Assays of cell migration were performed by using Transwell
chambers (10 mm diameter, 8 mm pores, Costar Corp.) as
described [27]. Capillary tube formation was performed as
described on growth factor-reduced Matrigel [27].
Confocal microscopy analysis
Microscopy was performed by using a Zeiss laser confocal
microscope system (LSM 510) connected to an Axiovert 100M
(Zeiss) and a Zeiss 63X objective. Images were acquired and
loaded by using a TCS NT program (version 1.6.587). No further
processing of the images was done except for changes in
brightness/contrast to better visualize the data. Images were
collected at 3.5 mm from the bottom and all conditions were
imaged at the same distance from the glass.
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Changes in intracellular calcium were determined using the
fluorescent calcium indicator Fluo-4 AM (Invitrogen). Cells were
seeded on Lab-Tek chambered #1.0 borosilicate coverglass
(LABTEK) for confocal live microscopy and serum starved
overnight. Each well was then incubated with 200 ml of HBSS
containing 0.5% BSA, 2 mM CaCl2, 4 mM Fluo-4 for 45 min at
37uC. Cells were then washed twice with HBSS containing 0.5%
BSA, 2 mM CaCl2 and incubated at 37uC in the same solution for
30 min to allow de-esterification of Fluo-4. Where indicated,
10 mM LY29400 was added after the first 15 minutes of the de-
esterification passage for 15 min. Samples were analyzed using the
Zeiss confocal microscope LSM 510 equipped with a chamber for
live imaging at 37uC supplied with 5% CO2 using a 10X objective.
After recording basal fluorescent, cells were stimulated with
100 ng/ml FGF-2 in the presence or in the absence of 10 mM
LY294002 and fluorescence was measured for 10 min. At the end
of each experiment, cells were stimulated with 1 mM ATP. ZEN
Carl Zeiss software was used for acquisition and analysis of raw
data. Fluorescence values of 40 cells per chamber were analyzed
and expressed as mean of fluorescence.
Results
FGF-2 activates PLCc1 in ECs
In order to determine whether PLCc1 is a downstream target of
FGF-2 in HUVEC we monitored the activation of the enzyme by
metabolic labelling of cells and analysis of the total amount of
inositol phosphates generated upon FGF-2 stimulation. Our data
show that FGF-2 increased the levels of inositol phosphates in
[
3H]-labelled HUVEC (Figure 1A) and induced Ca
2+ release from
intracellular stores (Figure 1B), indicating activation of a PLC
isoform. Downregulation of PLCc1 expression using specific
siRNA significantly reduced the FGF-2-dependent production of
inositol phosphates, indicating that this isoform is specifically
activated upon FGF-2 stimulation (Figure 1A). No reduction on
Figure 1. FGF-2 activates PLCc1 in ECs. (A) HUVEC were transfected with scrambled siRNA or specific siRNA to downregulate PLCc1 expression.
After 24 h cells were labelled with [
3H]myo inositol in M199 containing 2% FBS for a further 24 h and then stimulated with 100 ng/ml FGF-2 for the
indicated times. Data indicate the total amount of inositol phosphates generated at the indicated times and are expressed as percentage of the basal
inositol phosphates. Data are means6SEM of values obtained from 5 independent experiments. *p,0.05, **p,0.01. Blot shows PLCc1 expression in
lysates of HUVEC transfected with a control scrambled siRNA or siRNA targeting PLCc1. Equal loading of proteins was assessed by using an anti actin
antibody. (B) Intracellular calcium increase in serum starved HUVEC was determined as described in the Materials and Methods session. Cells were
stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times (arrows). Data are mean of values obtained from 4 independent experiments.
(C) Expression levels of PLCc1 or PLCc2 in HUVEC transfected with the indicated siRNAs. Equal loading was confirmed using anti Akt or anti ERK
antibodies. (D) HUVEC were transfected with scrambled siRNA or siRNAs targeting PLCc1 or PLCc2. The number of cells was determined by manual
counting 24 h or 48 h after transfection. Data are expressed as percentage of cells transfected with scrambled siRNA at each time point and are
means6SEM of values obtained from 6 independent experiments. *p,0.05, **p,0.01 vs HUVEC expressing siRNA PLCc1. In C and D siRNA targeting
PLCc2 were from Dharmacon.
doi:10.1371/journal.pone.0008285.g001
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observed in HUVEC transfected with the specific siRNA targeting
PLCc1 (Figure 1C). Interestingly, while PLCc1 downregulation
did not reduce the number of cells compared to HUVEC
transfected with a control scrambled siRNA, expression of a
specific siRNA targeting PLCc2 strongly reduced the number of
cells after 24 h or 48 h from transfection (Figure 1D). Similar
results were obtained using a distinct siRNA targeting PLCc2
(Figure S1). These data clearly indicate that PLCc1 and PLCc2
play distinct roles in HUVEC, with PLCc2 but not PLCc1 being
possibly involved in proliferation and/or survival of cells.
FGF-2-dependent PLCc1 activation requires PI3K
In an effort to define the mechanism of FGF-2-induced PLCc1
activation, we found that pre-treatment of cells with the reversible
PI3K inhibitor LY294002 significantly inhibited the FGF-2-
induced inositol phosphates production (Figure 2A). Similar results
were obtained using the irreversible PI3K inhibitor wortmannin
(Figure S2). Pre-treatment of cells with LY294002 completely
blocked FGF-2-induced intracellular calcium increase without
affecting the ATP-mediated release (Figure 2B). These data
indicate that PI3K is required for full activation of PLCc1,
consistent with evidence indicating that PI3K can have a role in
PLCc1 activation [24,28]. In addition we observed that the
isolated N-terminal PH domain of PLCc1 fused to green
fluorescent protein (GFP-PH PLCc1) translocated to the plasma
membrane of HUVEC upon FGF-2 stimulation (Figure S3).
Treatment of cells with wortmannin completely blocked this
translocation (Figure S3), suggesting that binding of PLCc1P H
domain to the FGF-2-dependent pool of PtdIns-3,4,5-P3 is
responsible for translocation to the plasma membrane and
subsequent activation of the enzyme. Taken together these data
indicate that FGF-2 is able to activate PLCc1 in ECs and that
PI3K is required for full activation of the enzyme. In contrast the
VEGF-dependent activation of PLCc1 was not dependent on
PI3K activity (Figure S4).
FGF-2 activates PI3K in ECs
To analyze in greater detail FGF-2-mediated PI3K activation in
HUVEC, we performed a time course analysis of PtdIns-3,4,5-P3
production in vivo by using TLC analysis of phospholipids
extracted from [
32P]-labelled HUVEC stimulated with FGF-2
for different times. The data indicate that FGF-2 generated
PtdIns-3,4,5-P3 with a peak at 5 and 10 min of stimulation
(Figure 3A). Confocal microscopy analysis using a specific anti
PtdIns-3,4,5-P3 antibody confirmed the FGF-2-induced produc-
tion of this phosphoinositide at the plasma membrane of HUVEC
(Figure 3B). These data indicate that FGF-2 rapidly and
transiently activates PI3K in HUVEC.
PLCc1 is necessary for FGF-2-dependent migration and
capillary tubule formation by ECs
The results so far indicated that FGF-2 can activate PLCc1i n
HUVEC and that PI3K activation is required for full activation of
the enzyme. Since we have reported that the PI3K-dependent
activation of PLCc1 is a key event in migration of breast cancer
cells [29] and PLCc1 is necessary for breast cancer migration and
invasion [30], we investigated whether this novel PI3K/PLCc1
pathway was involved in the FGF-2-dependent migration of
HUVEC. We have already reported that PI3K is required in such
process [27]. To test the role of PLCc1 we first examined the effect
of the PLC inhibitor U73122 on cell migration. Transwell assays
revealed that blockade of PLC activity completely abrogated the
FGF-2-induced migration in HUVEC whereas no significant
effect was observed when cells were treated with the inactive
structural analogue U73343 (Figure 4A). Moreover, downregula-
tion of PLCc1 using siRNA specifically inhibited FGF-2-
dependent migration of HUVEC (Figure 4B). These data indicate
that the PI3K/PLCc1 pathway is involved in FGF-2-induced cell
migration.
Since migration is a key step in angiogenesis, we then tested
whether PLCc1 was involved in this process by performing in vitro
angiogenesis assays. Capillary tubule formation assay on Matrigel
Figure 2. FGF-2 activates PLCc1 in a mechanism involving PI3K activation. (A) HUVEC were labelled with [
3H]myo inositol for 24 h and
then pre-treated with 10 mM LY294002 for 15 min before stimulation with 100 ng/ml FGF-2. Data indicate the total amount of inositol
phosphates generated at the indicated times and are expressed as percentages of the basal inositol phosphates. Data are means6SEM of values
obtained from 9 independent experiments. *p,0.05. (B) Calcium release from serum starved HUVEC untreated or treated with 10 mM LY294002.
Cells were stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times (arrows). Data are mean of values obtained from 2 independent
experiments.
doi:10.1371/journal.pone.0008285.g002
PI3K/PLCc1 in FGF Signalling
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8285revealed that treatment of HUVEC with the PLC inhibitor
U73122 completely blocked the formation of three-dimensional
structures whereas U73343 had no effect (Figure 5A). Similar
results were obtained upon PLCc1 downregulation in HUVEC
(Figure 5B). These data indicate that PLCc1 plays a key role in
FGF-2-dependent EC remodelling and angiogenesis, most likely
by regulating cell migration.
PLCc1 mediates Akt phosphorylation through PKCa
activation
We recently demonstrated that FGF-2-dependent migration and
tubulogenesis requires activation of the PI3K target PKB/Akt [27].
The observation that blockade of PLCc1 was able to inhibit both
processes prompted us to investigate whether a PLCc1-dependent
mechanism was involved in Akt activation. This hypothesis was
Figure 3. FGF-2 activates PI3K in HUVEC. (A) TLC analysis of phospholipids extracted from [
32P]-labelled HUVEC stimulated with 100 ng/ml FGF-
2 for the indicated times or 1 mM sphingosine-1-phosphate (S1P) for 5 min. Arrow indicates the PtdIns-3,4,5-P3 spot. (B) HUVEC grown on glass
coverslips were incubated overnight in M199+0.5%FBS before stimulation with 100 ng/ml FGF-2 for the indicated times. Coverslips were then
incubated with an anti PtdIns-3,4,5-P3 antibody and analyzed by confocal microscopy. Arrows indicate the plasma membrane localization of the
phosphoinositide. Bar=10 mm.
doi:10.1371/journal.pone.0008285.g003
Figure 4. PLCc1 is required for FGF-2-induced cell migration. (A) HUVEC were incubated overnight in M199+0.5%FBS before treatment with
5 mM U73122 or U73343 for 30 min. Migration of cells in the presence of 100 ng/ml FGF-2 was assessed by Transwell assays. Data are means6SEM of
values obtained from 7 independent experiments and are expressed as percentage of cells migrating in the absence of FGF-2 (control) ***p,0.001.
(B) HUVEC were transfected with scrambled siRNA or siRNA to downregulate PLCc1 expression. After 24 h cells were incubated overnight in
M199+0.5% FBS. Migration of cells in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are means6SEM of values
obtained from 7-10 independent experiments *p,0.05.
doi:10.1371/journal.pone.0008285.g004
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involved in Akt activation in ECs [31,32]. Since PLCc1 mediates
PKCa activation, we investigated whether PLCc1-mediated PKCa
activation was required for FGF-2-dependent Akt activation.
Blockade of PLC activity inhibited FGF-2-induced phosphorylation
of Akt at residue Ser473 in HUVEC (Figure 6A). No effect was
observed with the inactive analogue U73343 (Figure 6A). Further-
more we observed that treatment of cells with the conventional
PKC inhibitor Go ¨6976 (Figure 6B) and specific PKCa knock down
(Figure 6C) markedly inhibited the FGF-2-mediated Akt phosphor-
ylation, indicating that a PLCc1-mediated PKCa activation is
necessary for FGF-2-mediated Akt activation. Taken together these
data indicate that FGF-2-induced, PI3K-mediated Akt phosphor-
ylation at residue Ser473 depends on PLCc1 activation and
subsequent activation of PKCa.
PKCa is required for FGF-2-dependent migration
We next investigated the role of PKCa in Akt-dependent
cellular functions. In particular, since we observed that both
PLCc1 and Akt are required for FGF-2-dependent migration, we
investigated whether PKCa was also involved in this process.
Transwell assays revealed that PKC inhibition with Go ¨6976
(Figure 7A) completely blocked FGF-2-dependent migration of
HUVEC. Consistent with our previous work demonstrating the
role of Akt in FGF-2-induced migration of HUVEC [27] we found
that the Akt inhibitor SH5 strongly impaired cell migration
(Figure 7A) whereas no effect was observed using MEK inhibitors
(Figure 7A). Specific PKCa knock down also resulted in complete
inhibition of FGF-2-mediated cells migration (Figure 7B). These
data indicate that the novel PI3K/PLCc1/PKCa/Akt pathway is
involved in FGF-2-stimulated EC migration.
Discussion
Here we show that PLCc1 is activated upon FGF-2 stimulation
in HUVEC and that upstream activation of PI3K is required for
full activation of the enzyme. PLCc1 activation is necessary for
FGF-2-induced capillary tube formation in vitro. This process is the
result of distinct intracellular events (cell proliferation, apoptosis,
Figure 5. PLCc1 is necessary for FGF-2-induced tubulogenesis in vitro. (A) Representative images of HUVEC on Matrigel in the absence or
presence of FGF-2 plus 2 mM of the PLC inhibitor U73122 or its inactive analogue U73343. Plot represents a quantitative analysis of the experiments
obtainedbycountingthenumberofbranchpointsfromfivefields.Dataaremeans6SEMofvaluesobtainedfrom12independentexperiments.**p,0.01.
NS=not significant. (B) Representative images of HUVEC transfected with the scrambled siRNA or siRNA targeting PLCc1 on Matrigel in the presence of
FGF-2. Quantitative analysis show data as means6SEM of values obtained from 5 independent experiments. NS=not significant.
doi:10.1371/journal.pone.0008285.g005
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tubulogenesis is associated with its role in cell migration.
The mechanisms of FGF-dependent activation of PI3K and
PLCc1 have been controversial. Early studies showed that p85, the
regulatory subunit of PI3K, did not coimmunoprecipitate with
FGFR1 and no PI3K activity was detected in anti FGFR1
immunoprecipitates [33]. However, subsequent work revealed that
FGF-2 increases PI3K activity in anti-p85 or anti-p110 immuno-
precipitates [34] and that assembly of a multi-docking protein
complex is necessary for the FGF-2-mediated activation of PI3K
[17]. By directly monitoring generation of its lipid product PtdIns-
3,4,5-P3, we demonstrate here that FGF-2 activates PI3K in
HUVECs and that this enzyme is involved in PLCc1 activation.
Although FGF-induced PLCc1 phosphorylation and activation
Figure 6. PLCc1-dependent PKCa activation mediates FGF-2-induced Akt activation. HUVEC were incubated overnight in M199+0.5%FBS
and then treated with the indicated concentrations of U73122 or U73343 for 30 min (A) or 10 mM of the conventional PKCs inhibitor Go ¨6976 (B) before
stimulation with 100 ng/ml FGF-2 for 10 min. (C) HUVEC were transfected with scrambled siRNA or siRNAs targeting PKCa. After 24 h cells were serum
deprived overnight andthenstimulated with 100 ng/mlFGF-2for the indicated times.Phosphorylationof AktatSer473 wasassessed byusing a specific
antibody. Membranes were then stripped and re-probed with an anti Akt. Blots are representative of 7 (A) and 3 (B,C) independent experiments. In all
cases, quantitative analysis of the band intensities was performed. Data represent values of pSer473 Akt/Akt expressed as fold increase over control.
doi:10.1371/journal.pone.0008285.g006
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lines overexpressing FGFR1 [35], other studies reported that FGF
was not able to induce PLCc1 tyrosine phosphorylation and
activation in choroidal ECs [36]. Similarly, no tyrosine phosphor-
ylation of PLCc1 was detected in FGF-stimulated HUVEC [37],
although total inositol phosphates production was not monitored in
this study. Here we demonstrate that FGF-2 is indeed able to
stimulate PLC activity. Moreover selective downregulation of
PLCc1 reveals the specific activation of this isoform upon FGF-2
stimulation, in agreement with the reported FGF-2-dependent
PLCc1 activation in corneal ECs [38]. Although the time course of
stimulation performed in the previous report was different
compared to our study, it is interesting to notice that the fold
increase of total inositol phosphates accumulation upon 1 h of FGF-
2 stimulation is very similar between the two studies. We further
show that downregulation of PLCc1 does not affect the expression
levels of the related PLC isoform PLCc2. Interestingly, downreg-
ulation of PLCc2 but not PLCc1 specifically reduces the number of
cells compared to HUVECs expressing a scrambled siRNA,
suggesting a potential role for PLCc2 in proliferation and/or
survival of cells. These results are consistent with accumulating
evidence revealing distinct, not overlapping functions for PLCc1
and PLCc2 [39–42].
Our study indicates that PI3K activation is required for PLCc1
activation, consistent with our previous work describing the
interaction of PLCc1 PH domain with the PI3K product PtdIns-
3,4,5-P3 and its role in membrane targeting of the enzyme [24] and
with evidence indicating that tyrosine phosphorylation is not
sufficient for PLCc1 activity [28,43,44]. Our data clearly indicate
that monitoring PLCc1 activation only by analysing its tyrosine
phosphorylation does not take into account the possibility of
additional and/or alternative mechanisms of activation of the
enzyme [28]. In this respect it must be observed that, although no
activation of PLCc1 was detected in porcine aortic ECs
overexpressing a mutant FGFR1 unable to induce tyrosine
phosphorylation of PLCc1 (FGFR1 Y766F) [45], a detailed analysis
of PLCc1 activation at different times of stimulation was not
performed in this report. Indeed by performing accurate time
course experiments we observed that at specific time points a PI3K-
dependent PLC activity can be detected in cell lines overexpressing
the FGFR1 Y766F mutant (data not shown). It must be noted that
PI3K is involved in FGF-2-dependent but not in VEGF-dependent
PLCc1 activation suggesting that different mechanisms of PLCc1
activation exist in different cellular contexts.
We further show that the PI3K-dependent PLCc1 activation is
required for FGF-2-dependent migration of HUVEC. Previous
data indicated that PLCc1 was not required for migration
downstream of FGFR1 activation [45] but it must be noted that
these data were obtained in cells overexpressing the FGFR1
Y766F mutant therefore in the absence of PLCc1 tyrosine
phosphorylation. Since these cells were still able to migrate in
response to FGFR1 activation it was concluded that PLCc1 had
no role in this process [45]. However, as discussed above, such a
conclusion did not take into account the possibility of the PI3K-
mediated activation of PLCc1. The role of PLCc1i nE C
migration is consistent with the reported role of this enzyme in
cell migration, invasion and spreading of other cell types [46–49].
In particular we demonstrated that PI3K-mediated PLCc1
activation is required for epidermal growth factor-induced
migration of breast cancer cells [29]. More recently, we reported
that PLCc1 is required for breast cancer cells migration and
invasion [30]. Our present and previous data indicate that both
PI3K [27] and PLCc1 are required for FGF-2-induced tubulo-
genesis in vitro. Recent data have suggested that PI3K and PLCc1
have opposite effects on capillary tube formation in vitro with PI3K
promoting tubule formation and PLCc1 regulating tubule
regression [50]. The apparent discrepancies between this report
and our present data are likely due to the different experimental
conditions. Furthermore, our results are in agreement with data
demonstrating the key role of PLCc1 in HUVEC cell elongation
and network formation on Matrigel [49]. Our data reveal that the
FGF-2-induced tubule formation is also dependent on PLCc1
activation. It must be pointed out that we cannot completely rule
out the possibility that in our experimental conditions the detected
Figure 7. PKCa is required for FGF-2-induced cell migration. (A) HUVEC were incubated overnight in M199+0.5%FBS before treatment with
2 mMG o ¨6796, 50 mMo r1 0mM of the MEK inhibitors PD98059 and U0126 respectively or 50 mM of the Akt inhibitor SH5 for 30 min. Migration of cells
in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are means6SEM of values obtained from 2-7 independent
experiments *p,0.05, **p,0.01. (B) HUVEC were transfected with scrambled siRNA or siRNA to downregulate PKCa expression. After 24 h cells were
incubated overnight in M199+0.5% FBS. Migration of cells in the presence of 100 ng/ml FGF-2 was then assessed by Transwell assays. Data are
means6SEM of values obtained from 5 independent experiments **p,0.01.
doi:10.1371/journal.pone.0008285.g007
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The possibility exists that FGF-2 stimulation of HUVEC upon
overnight serum starvation induces survival of cells which are then
able to migrate in response to extracellular matrix components, as
previously reported [49]. Nevertheless our data indicate the key
role of PLCc1 in this process, suggesting that activation of a
PI3K/PLCc1 pathway is involved in FGF-2-dependent angio-
genesis. This would be consistent with recent data in literature.
Indeed it has been reported that y10 (the zebra fish homologue of
PLCc1) mutant embryos display specific defect in the formation of
arteries, but not veins [23]. Sequence analysis revealed that the
majority of the mutations in y10 mutants occur in the PH domain
[23] and in particular in the b3/b4 region of the PH domain that
we demonstrated to be important for PtdIns-3,4,5-P3 binding and
growth factor-induced membrane localization of PLCc1 [24].
These data suggest that a PI3K-dependent regulation of PLCc1
might be involved in vasculogenesis.
In an effort to define the mechanism of PLCc1-dependent
regulation of EC tubulogenesis we found that activation of a
PLCc1/PKCa pathway is necessary for FGF-2-induced Akt
phosphorylation. Akt is involved in physiological and pathological
angiogenesis through effects in both EC and cells producing
endothelial signals such as tumour cells [51-55]. Furthermore Akt is
required for EC migration [56] and we reported that this enzyme is
necessary for both FGF-2-induced migration and tubulogenesis in
HUVEC [27]. Akt activation requires its phosphorylation at
Thr308 by phosphoinositide-dependent kinase-1 [57,58] and at
Ser473. Although the mTORC2 complex, containing the enzyme
mammalian target of rapamycin, has been shown to mediate
Ser473 phosphorylation in several cell types [59], the precise
mechanism of Akt Ser473 phosphorylation and the link between
PI3K and this crucial event in Akt activation remains unclear. Our
data here reveal a novel and critical role for a PLCc1/PKCa
pathway in mediating FGF stimulation of Akt phosphorylation at
Ser473. This data is consistent with previous reports indicating a
role for PKC in Akt phosphorylation in ECs [31,32]. Interestingly it
was recently reported that a PLCc1-dependent PKC activation is
necessary for Akt phosphorylation at Ser473 in monocytes
stimulated with phospholipase A2-modified low density lipoprotein
[60]. On the other hand, we did not detect impairment of Ser473
Akt phosphorylation in breast cancer cells stimulated with
epidermal growth factor upon downregulation of PLCc1 [30]
suggesting that the role of PLCc1 in mediating Akt phosphorylation
may be cell and stimulus specific. Due to the variety of intracellular
events requiring Akt activation it is likely that identification of
PLCc1 as a key mediator in its activation will lead to the discovery
of novel roles for PLCc1 in different intracellular functions.
EC lining the lumen of all blood vessels play essential roles in
maintaining normal vascular function and in vascular homeostasis
[1]. EC migration is a crucial step in angiogenesis and is essential
for regeneration of endothelia damaged by balloon catheter
angioplasty and stent placement. Furthermore EC migration is a
prerequisite for the formation of collateral blood vessels in
ischaemic heart and peripheral vascular disease [1]. A better
understanding of the factors and intracellular processes governing
EC migration will have profound implications not only for
cardiovascular disease but also for a better understanding of
embryogenesis and reproduction. Furthermore due to the
emerging role of FGF-2 in tumour angiogenesis and its potential
role in drug resistance to anti-angiogenic agents, understanding
the FGF-dependent signalling pathways will prove useful to design
novel potential strategies of intervention. In this respect our
present data, together with our previous work indicating the
critical role of PLCc1 in metastasis development and progression
[30] suggest that targeting PLCc1 may represent a useful strategy
to inhibit metastasis growth and possibly tumour angiogenesis
simultaneously. In this respect identification of PLCc1 as a critical
player in regulation of FGF-induced EC migration and tubulo-
genesis and in modulating Akt activation will have both biological
and potential therapeutic implications.
Supporting Information
Figure S1 Effects of downregulation of PLCc1 and PLCc2o n
HUVEC. (A) Expression levels of PLCc1 or PLCc2 in HUVEC
transfected with the indicated siRNAs. Equal loading was
confirmed using anti Akt or anti ERK antibodies. (B) HUVEC
were transfected with scrambled siRNA or siRNAs targeting
PLCc1 or PLCc2. After 24 h, cells were starved overnight in
M199+0.5% FBS and then the number of cells was determined by
manual counting. Data are expressed as percentage of cells
transfected with scrambled siRNA and are means6SEM of values
obtained from 5 independent experiments. *p,0.05, **p,0.01 vs
HUVEC expressing siRNA PLCc1. In these experiments siRNA
targeting PLCc2 was from Qiagen.
Found at: doi:10.1371/journal.pone.0008285.s001 (1.56 MB TIF)
Figure S2 FGF-2 activates PLCc1 in a mechanism involving
PI3K activation. HUVEC were labelled with [3H]myo inositol for
24 h and then pre-treated with 100 nM wortmannin for 15 min
before stimulation with 100 ng/ml FGF-2. Data indicate the total
amount of inositol phosphates generated at the indicated times and
are expressed as percentages of the basal inositol phosphates. Data
are means6SEM of values obtained from 1–2 independent
experiments.
Found at: doi:10.1371/journal.pone.0008285.s002 (3.73 MB TIF)
Figure S3 PI3K regulates FGF-2-induced PLCc1 recruitment to
the plasma membrane. HUVEC were transfected with a GFP-
tagged PLCc1 PH domain and plated on glass coverslips. After
24 h cells were serum deprived overnight in M199+0.5% FBS and
then left untreated or pre-treated with 100 nM wortmannin for
15 min before stimulation with 100 ng/ml FGF-2 for 10 min.
Coverslips were fixed and analyzed by confocal microscopy.
Found at: doi:10.1371/journal.pone.0008285.s003 (6.24 MB TIF)
Figure S4 VEGF-mediated activation of PLCc1 is not depen-
dent on PI3K activation. HUVEC were labelled with [3H]myo
inositol for 24 h and then pre-treated with 10 mM LY294002 (A)
or 100 nM wortmannin (B) for 15 min before stimulation with
10 ng/ml VEGF. Data indicate the total amount of inositol
phosphates generated at the indicated times and are expressed
as percentages of the basal inositol phosphates. Data are
means6SEM of values obtained from 1–3 (A) or 1–4 independent
experiments (B).
Found at: doi:10.1371/journal.pone.0008285.s004 (6.07 MB TIF)
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